Major adverse cardiovascular events in adult congenital heart disease: a population-based follow-up study from Taiwan

Table 4 Hazard ratios of incident MACE adjusted for age and sex for early and late study periods in various ConHD patients with and without surgery history

	Surgery	non-Surgey	Follow-up time: ≥1.5 years		Follow-up time: 1.5 to 3 years		Follow-up time: Over 3 years
	n/N	n/N	Adjusted HR (95% CI)	Pvalue	Adjusted HR (95% CI)	Pvalue	Adjusted HR (95% CI)	Pvalue
ConHD	114/1124	309/1486	0.47 (0.38, 0.58)	<.0001	0.39 (0.28, 0.56)	<.0001	0.52 (0.40, 0.69)	<.0001
1.Cyanotic	6/62	35/151	0.34 (0.14, 0.81)	0.015	0.28 (0.06, 1.22)	0.091	0.38 (0.13, 1.12)	0.08
TOF	3/29	32/144	0.42 (0.13, 1.37)	0.149	0.67 (0.15, 3.00)	0.598	0.24 (0.03, 1.79)	0.164
2.Non-Cyanotic	108/1062	274/1335	0.48 (0.39, 0.61)	<.0001	0.40 (0.28, 0.58)	<.0001	0.55 (0.41, 0.73)	<.0001
VSD	18/237	99/694	0.55 (0.33, 0.92)	0.021	0.24 (0.08, 0.79)	0.019	0.74 (0.42, 1.31)	0.298
ASD	62/624	125/463	0.34 (0.25, 0.46)	<.0001	0.27 (0.17, 0.43)	<.0001	0.41 (0.27, 0.61)	<.0001
PDA	19/125	26/114	0.68 (0.37, 1.25)	0.211	0.82 (0.36, 1.88)	0.643	0.55 (0.22, 1.34)	0.185

MACE, major adverse cardiovascular events; ConHD, congenital heart disease; Cyanotic, cyanotic congenital heart disease; TOF, Tetrtology of fallot; Non-cyanotic, non-cyanotic congenital heart disease; VSD, ventricular septal defect; ASD, ostium or secundum type atrial septal defect; PDA, patent ductus arteriosus; PS, congenital stenosis of pulmonary valve. n, number of subjects with MACE; N, total number of subjects; Adjusted HR (95% CI), hazard ratio for incident MACE (95% confidence interval) adjusted for age and sex.

ISSN: 1471-2261